These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 22661759)
1. Standard 3: data monitoring committees. Ellenberg S; Fernandes RM; Saloojee H; Bassler D; Askie L; Vandermeer B; Offringa M; Van der Tweel I; Altman DG; van der Lee JH; Pediatrics; 2012 Jun; 129 Suppl 3():S132-7. PubMed ID: 22661759 [No Abstract] [Full Text] [Related]
2. Committee for Medicinal Products for Human Use (CHMP) guideline on Data Monitoring Committees. ; ; Stat Med; 2006 May; 25(10):1639-45. PubMed ID: 16639775 [No Abstract] [Full Text] [Related]
3. An introductory note to CHMP guidelines: choice of the non-inferiority margin and data monitoring committees. Brown D; Volkers P; Day S Stat Med; 2006 May; 25(10):1623-7. PubMed ID: 16639776 [TBL] [Abstract][Full Text] [Related]
4. An introductory note to the CHMP guidelines: choice of the non-inferiority margin and data monitoring committees by David Brown, Peter Volkers and Simon Day, Statistics in Medicine 2006; 25:1623-1627. Stat Med; 2007 Jan; 26(1):230-3; author reply 234-5. PubMed ID: 16900566 [No Abstract] [Full Text] [Related]
8. When should data and safety monitoring committees share interim results in cardiovascular trials? Borer JS; Gordon DJ; Geller NL JAMA; 2008 Apr; 299(14):1710-2. PubMed ID: 18398083 [No Abstract] [Full Text] [Related]
9. Data safety and monitoring boards for African clinical trials. Lang T; Chilengi R; Noor RA; Ogutu B; Todd JE; Kilama WL; Targett GA Trans R Soc Trop Med Hyg; 2008 Dec; 102(12):1189-94. PubMed ID: 18644610 [TBL] [Abstract][Full Text] [Related]
11. Conflicts of interest in data monitoring of industry versus publicly financed clinical trials. Lachin JM Stat Med; 2004 May; 23(10):1519-21. PubMed ID: 15122730 [TBL] [Abstract][Full Text] [Related]
12. Data safety monitoring boards: a word from a sponsor (NHLBI). Mondoro TH Transfusion; 2009 Aug; 49(8):1537-9. PubMed ID: 19413736 [No Abstract] [Full Text] [Related]
16. Access to clinical trial data. Data monitoring committees and selective outcome reporting. Ting JY BMJ; 2011 Feb; 342():d635. PubMed ID: 21285218 [No Abstract] [Full Text] [Related]
17. Independence of the statistician who analyses unblinded data. Siegel JP; O'Neill RT; Temple R; Campbell G; Foulkes MA Stat Med; 2004 May; 23(10):1527-9. PubMed ID: 15122732 [TBL] [Abstract][Full Text] [Related]
18. Stopping guidelines for harm in a study designed to establish the safety of a marketed drug. Fleishman AN; Parker RA J Biopharm Stat; 2012; 22(2):338-50. PubMed ID: 22251178 [TBL] [Abstract][Full Text] [Related]
19. Stopping guidelines for an effectiveness trial: what should the protocol specify? Tyson JE; Pedroza C; Wallace D; D'Angio C; Bell EF; Das A Trials; 2016 May; 17(1):240. PubMed ID: 27165260 [TBL] [Abstract][Full Text] [Related]
20. Reporting standards for adverse events after medical device use in the peripheral vascular system. Ouriel K; Fowl RJ; Davies MG; Forbes TL; Gambhir RP; Morales JP; Ricci MA; J Vasc Surg; 2013 Sep; 58(3):776-86. PubMed ID: 23972246 [No Abstract] [Full Text] [Related] [Next] [New Search]